Tiotropium bromide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Chronic Obstructive Pulmonary Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Spiriva (tiotropium bromide hydrate), Nippon Boehringer Ingelheim: new bronchial asthma indication
Product first approved 2014pj.jiho.jp
EU
  • Spiriva Respimat: add-on maintenance bronchodilator treatment in adult patients with asthma who had one or more severe exacerbations in the previous year
Product first approved 2014medthority.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (73)
Asthma
NCT02066298 · Milton S. Hershey Medical Center
2014-07 – 2018-05 · Asthma
What this study did
NCT01634139 · Boehringer Ingelheim
2012-07 – 2015-12 · Asthma
What this study did
NCT01634152 · Boehringer Ingelheim
2012-07 – 2015-05 · Asthma
What this study did
NCT01257230 · Boehringer Ingelheim
2010-12 – 2013-12 · Asthma
What this study did
NCT01277523 · Boehringer Ingelheim
2011-01 – 2013-10 · Asthma
What this study did
NCT01290874 · Brigham and Women's Hospital
2011-03-30 – 2013-07 · Asthma
What this study did
NCT01316380 · Boehringer Ingelheim
2011-03 – 2012-04 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT05161156 · Phargentis SA
2022-03-24 – 2022-11-29 · COPD
What this study did
NCT05927155 · Erasme University Hospital
2021-06-15 – 2022-03-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03745261 · Henan University of Traditional Chinese Medicine
2018-06-20 – 2020-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03137992 · Lupin, Inc.
2017-11-21 – 2018-04-30 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02683668 · Imperial College London
2016-02-01 – 2018-01-01 · COPD, LUNG DISEASES, OBSTRUCTIVE
What this study did
NCT02796677 · AstraZeneca
2016-07-05 – 2017-06-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01696058 · Boehringer Ingelheim
2012-09 – 2013-10 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01536262 · Boehringer Ingelheim
2012-02 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01525615 · Boehringer Ingelheim
2012-02 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01694771 · Boehringer Ingelheim
2012-09 – 2013-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01126437 · Boehringer Ingelheim
2010-05 – 2013-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01119937 · Novartis Pharmaceuticals
2010-05 – 2011-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01012765 · Novartis Pharmaceuticals
2009-11 – 2011-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00999908 · Novartis Pharmaceuticals
2009-10 – 2010-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00662792 · Boehringer Ingelheim
2008-04-15 – 2009-07-22 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00673478 · Boehringer Ingelheim
2008-05 – 2009-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00387088 · Boehringer Ingelheim
2006-09 – 2009-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00668772 · Boehringer Ingelheim
2008-04-15 – 2008-11-21 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00662740 · Boehringer Ingelheim
2008-04-15 – 2008-11-21 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00144339 · Boehringer Ingelheim
2002-12 – 2008-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00308191 · Dey
2006-04 – 2006-12 · COPD
What this study did
NCT00157235 · Boehringer Ingelheim
2002-09 – 2006-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00168831 · Boehringer Ingelheim
2003-02 – 2005-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00168844 · Boehringer Ingelheim
2003-01 – 2005-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00277264 · Boehringer Ingelheim
2002-01 – 2004-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239447 · Boehringer Ingelheim
2002-11-26 – 2004-04-29 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00274053 · Boehringer Ingelheim
2002-04 – 2004-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239460 · Boehringer Ingelheim
2003-07 – 2004-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00239473 · Boehringer Ingelheim
2002-11 – 2003-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00240435 · Boehringer Ingelheim
2002-11 – 2003-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00274014 · Boehringer Ingelheim
2000-10 – 2003-10 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 2/3 (1)
Asthma
NCT03358147 · Pearl Therapeutics, Inc.
2017-12-13 – 2019-09-12 · Asthma
What this study did
Phase 2 (38)
Asthma
NCT04990167 · Nemours Children's Clinic
2022-01-01 – 2025-10-31 · Asthma in Children
What this study did
NCT01383499 · Boehringer Ingelheim
2011-08 – 2012-09 · Asthma
What this study did
NCT01122680 · Boehringer Ingelheim
2010-05 – 2011-04 · Asthma
What this study did
NCT00557700 · University Hospital, Ghent
2008-01 – 2010-05 · Asthma
What this study did
NCT00350207 · Boehringer Ingelheim
2006-07 – 2008-09 · Asthma
What this study did
NCT00365560 · Boehringer Ingelheim
2006-08 – 2007-11 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT05838703 · Duke University
2023-05-01 – 2024-05-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT04780984 · Nephron Pharmaceuticals Corporation
2020-11-01 – 2021-04-26 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT03937479 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2019-05-01 – 2019-11-15 · COPD
What this study did
NCT03673670 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2018-07-16 – 2018-11-13 · COPD
What this study did
NCT03028142 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2017-01 – 2017-08 · Chronic Obstructive Pulmonary Disease Moderate
What this study did
NCT03118765 · Glenmark Specialty S.A.
2017-03-24 – 2017-07-31 · Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02203474 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-08 – 2014-08 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01222533 · Boehringer Ingelheim
2010-10 – 2011-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01040403 · Boehringer Ingelheim
2010-01 – 2011-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00528996 · Boehringer Ingelheim
2007-09-06 – 2009-05-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00720499 · Boehringer Ingelheim
2008-07 – 2009-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00696020 · Boehringer Ingelheim
2008-06 – 2009-02 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00535366 · Boehringer Ingelheim
2007-10 – 2008-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00515502 · GlaxoSmithKline
2007-06-21 – 2007-11-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00422604 · GlaxoSmithKline
2006-10 – 2007-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00292448 · Boehringer Ingelheim
2006-02 – 2007-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00128440 · Boehringer Ingelheim
2005-08 – 2006-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00325169 · GlaxoSmithKline
2005-12 – 2006-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00122434 · Boehringer Ingelheim
2005-07 – 2006-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02238119 · Boehringer Ingelheim
2002-02 – 2002-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02242240 · Boehringer Ingelheim
2001-03 – 2001-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02175342 · Boehringer Ingelheim
1998-03-01 – 1999-04-01 · Pulmonary Disease, Chronic Obstructive
What this study did
Other / comorbidity
NCT02586649 · James J. Peters Veterans Affairs Medical Center
2014-07 – 2019-12 · Spinal Cord Injury
What this study did
NCT01172925 · Hamilton Health Sciences Corporation
2010-11 – 2016-08 · NSCLC, Dyspnea
What this study did
NCT00737100 · Boehringer Ingelheim
2008-09 – 2010-04 · Cystic Fibrosis
What this study did
Phase 1/2 (1)
Chronic Obstructive Pulmonary Disease
NCT01785433 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-01 – 2013-08 · COPD
What this study did
Phase 1 (34)
Chronic Obstructive Pulmonary Disease
NCT07267130 · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
2025-11-25 – 2026-08-21 · Chronic Obstructive Pulmonary Disease
What this study did
NCT06487416 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-06-10 – 2024-10 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT06326671 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-02-28 – 2024-04 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02969317 · Boehringer Ingelheim
2017-02-24 – 2017-06-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02573155 · AstraZeneca
2015-10 – 2016-08 · Asthma (Part 1), COPD (Part 2)
What this study did
NCT02441114 · Seoul National University Hospital
2015-07 – 2015-10 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01703845 · Boehringer Ingelheim
2012-10 – 2013-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00870896 · ThomasTruncale
2008-02 – 2012-06 · Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
What this study did
NCT02231177 · Boehringer Ingelheim
2008-06 – 2008-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00555022 · GlaxoSmithKline
2007-12-12 – 2008-04-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00279019 · GlaxoSmithKline
2005-12-12 – 2006-06-13 · Pulmonary Disease, Chronic Obstructive
What this study did
Other / comorbidity
NCT05246046 · Orion Corporation, Orion Pharma
2022-02-16 – 2022-08-03 · Healthy Volunteers
What this study did
NCT04850144 · Orion Corporation, Orion Pharma
2021-04-26 – 2021-10-04 · Healthy Volunteers
What this study did
NCT03945344 · Orion Corporation, Orion Pharma
2019-05-27 – 2019-06-19 · Healthy Volunteer Study
What this study did
NCT03246581 · Kindeva Drug Delivery
2017-07-13 – 2018-05-03 · Healthy
What this study did
NCT03400241 · Orion Corporation, Orion Pharma
2018-02-19 – 2018-04-18 · Healthy Subjects
What this study did
NCT03155204 · Solventum US LLC
2017-04-25 – 2018-03-19 · Healthy
What this study did
NCT03302065 · Solventum US LLC
2016-05 – 2017-01 · Healthy
What this study did
NCT01355991 · James J. Peters Veterans Affairs Medical Center
2011-08 – 2016-08 · Spinal Cord Injury
What this study did
NCT02676297 · Solventum US LLC
2016-01 – 2016-07 · Healthy
What this study did
NCT02627625 · Solventum US LLC
2015-11 – 2016-06 · Healthy
What this study did
NCT02172534 · Boehringer Ingelheim
2006-09 – 2008-09 · Cystic Fibrosis
What this study did
NCT00257452 · Boehringer Ingelheim
2004-10 – 2005-07 · Healthy
What this study did
NCT02263976 · Boehringer Ingelheim
2003-08 – 2004-06 · Healthy
What this study did
NCT02172781 · Boehringer Ingelheim
2001-01 – 2001-04 · Healthy
What this study did
NCT02172417 · Boehringer Ingelheim
2000-07 – 2000-11 · Healthy
What this study did
NCT02177305 · Boehringer Ingelheim
1998-10 – 1998-12 · Healthy
What this study did
NCT02172339 · Boehringer Ingelheim
1998-04 – 1998-12 · Renal Insufficiency
What this study did
Phase 4 (77)
Asthma
NCT06679465 · University of Saskatchewan
2025-01-01 – 2027-01 · Asthma Bronchiale
What this study did
NCT05113615 · University of Saskatchewan
2021-12-13 – 2022-05-06 · Asthma
What this study did
NCT04648813 · University of Saskatchewan
2020-11-13 – 2021-04-20 · Allergic Asthma
What this study did
NCT03199976 · Helsinki University Central Hospital
2016-04-20 – 2020-11-18 · Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
What this study did
NCT02039011 · University of Dundee
2014-02 – 2016-07 · Asthma
What this study did
NCT02622243 · University of Saskatchewan
2015-11 – 2016-03 · Asthma
What this study did
NCT00546234 · University of Alberta
2007-11 – 2014-01 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT04061161 · University Medical Center Groningen
2019-08-19 – 2023-12-31 · COPD
What this study did
NCT04231214 · Fraunhofer-Institute of Toxicology and Experimental Medicine
2020-01-28 – 2023-04-18 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03964207 · Boehringer Ingelheim
2019-11-25 – 2021-11-16 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02872090 · Centre Hospitalier Universitaire de Besancon
2016-03 – 2021-06-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02546297 · Shanghai Pulmonary Hospital, Shanghai, China
2017-09-15 – 2021-03-01 · COPD, Bronchiectasis
What this study did
NCT03275116 · Maastricht University Medical Center
2017-07-07 – 2020-12 · Chronic Obstructive Airway Disease
What this study did
NCT04223843 · Boehringer Ingelheim
2020-01-08 – 2020-09-29 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03219866 · Wake Forest University Health Sciences
2017-10-03 – 2020-04-01 · COPD, COPD Exacerbation
What this study did
NCT04520230 · Tanta University
2014-10-31 – 2019-12-31 · COPD
What this study did
NCT03152149 · University of Dundee
2017-06-01 – 2019-11-26 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02813200 · University Hospital, Bordeaux
2017-01-10 – 2019-03-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02567214 · Laval University
2016-06 – 2018-11-30 · COPD
What this study did
NCT02812862 · RWTH Aachen University
2016-08 – 2018-08 · COPD
What this study did
NCT03425617 · Queen's University
2017-01-01 – 2018-06-30 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03055988 · Boehringer Ingelheim
2017-03-29 – 2018-03-26 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02988869 · Neutec Ar-Ge San ve Tic A.Ş
2016-08 – 2017-08 · COPD
What this study did
NCT02683109 · Boehringer Ingelheim
2016-03-08 – 2017-01-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01455129 · The First Affiliated Hospital of Guangzhou Medical University
2011-11 – 2016-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01656005 · University of Dundee
2012-08 – 2016-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02546349 · Taipei Veterans General Hospital, Taiwan
2014-07 – 2016-01 · COPD
What this study did
NCT01794780 · Novartis Pharmaceuticals
2013-02-05 – 2015-05-25 · COPD
What this study did
NCT02125734 · Novartis Pharmaceuticals
2014-04 – 2015-01 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01466712 · KU Leuven
2011-11 – 2014-12 · COPD, Emphysema, Small Airway Disease
What this study did
NCT01959516 · Novartis Pharmaceuticals
2014-02 – 2014-10 · COPD
What this study did
NCT01663987 · Boehringer Ingelheim
2012-08-01 – 2014-05-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01662986 · Boehringer Ingelheim
2012-08-01 – 2014-04-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01922271 · Novartis Pharmaceuticals
2013-08 – 2014-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01751113 · GlaxoSmithKline
2013-02 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01693003 · Irmandade Santa Casa de Misericórdia de Porto Alegre
2013-03 – 2013-10 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00975195 · Boehringer Ingelheim
2009-02 – 2013-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01397890 · AstraZeneca
2011-07 – 2013-06 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01644734 · Boehringer Ingelheim
2011-11 – 2013-03 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01483625 · Boehringer Ingelheim
2011-11 – 2012-12 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01072396 · Boehringer Ingelheim
2010-02 – 2011-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01307189 · Laval University
2005-04 – 2010-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00523991 · Boehringer Ingelheim
2007-04 – 2010-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00525512 · Boehringer Ingelheim
2007-08 – 2010-06 · Pulmonary Disease, Chronic Obstructive, Exercise
What this study did
Early phase / not applicable (12)
Asthma
NCT04696965 · Chang Gung Memorial Hospital
2021-03-04 – 2023-11-20 · Asthma
What this study did
NCT00706446 · Brigham and Women's Hospital
2008-06 – 2011-09 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT07541378 · Medical University of Bialystok
2024-03-11 – 2027-09-01 · COPD (Chronic Obstructive Pulmonary Disease)
What this study did
NCT03842839 · Guangzhou Institute of Respiratory Disease
2019-08-01 – 2025-05-07 · Airway Remodeling, Chronic Obstructive Pulmonary Disease
What this study did
NCT05295355 · Guangzhou Institute of Respiratory Disease
2021-01-25 – 2025-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04994574 · Yonsei University
2021-08-23 – 2024-07-25 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04999930 · National University of Malaysia
2020-01-10 – 2021-02-28 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03504527 · Huashan Hospital
2018-05-01 – 2019-05-01 · Asthma-COPD Overlap
What this study did
NCT03258749 · Huashan Hospital
2017-11-01 – 2018-10-31 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02331940 · University of Crete
2010-03 – 2014-09 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00981851 · Radboud University Medical Center
2009-09 – 2011-05 · Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Smoking, Bronchodilation
What this study did
Other / comorbidity
NCT04137029 · Federal State Budgetary Institution, Pulmonology Scientific Research Institute
2019-04-24 – 2020-10 · Health, Subjective, Hyperreactivity, Bronchial
What this study did
Used as active comparator (81)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (44)
Asthma
NCT03158311 · Novartis Pharmaceuticals
2018-02-05 – 2019-07-19 · Asthma
What this study did
NCT02676089 · Chiesi Farmaceutici S.p.A.
2016-04-06 – 2018-05-28 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT03095456 · Mylan Inc.
2017-03-27 – 2017-11-25 · Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
What this study did
NCT02518139 · Mylan Inc.
2015-09 – 2017-06 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01837927 · Novartis Pharmaceuticals
2014-04 – 2016-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01911364 · Chiesi Farmaceutici S.p.A.
2014-01 – 2016-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02276222 · Sunovion Respiratory Development Inc.
2014-10 – 2016-02 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02207829 · GlaxoSmithKline
2014-09-01 – 2015-06-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02257385 · GlaxoSmithKline
2014-10-15 – 2015-05-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01970878 · Pearl Therapeutics, Inc.
2013-11 – 2015-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01854645 · Pearl Therapeutics, Inc.
2013-05 – 2015-02 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01964352 · Boehringer Ingelheim
2013-11 – 2014-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02006732 · Boehringer Ingelheim
2013-11 – 2014-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01513460 · Novartis Pharmaceuticals
2012-04 – 2013-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01431287 · Boehringer Ingelheim
2011-09 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01533935 · Boehringer Ingelheim
2012-02 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01533922 · Boehringer Ingelheim
2012-03 – 2013-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01431274 · Boehringer Ingelheim
2011-09 – 2013-09 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01559116 · Boehringer Ingelheim
2012-03 – 2013-08 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01574651 · Novartis Pharmaceuticals
2012-05 – 2013-04 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01613326 · Novartis Pharmaceuticals
2012-06 – 2013-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01285492 · Novartis Pharmaceuticals
2011-01 – 2012-09 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01395888 · GlaxoSmithKline
2011-06-30 – 2012-08-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01490125 · Novartis Pharmaceuticals
2011-10 – 2012-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00845728 · Novartis Pharmaceuticals
2009-03 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01120691 · Novartis Pharmaceuticals
2010-04 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01316900 · GlaxoSmithKline
2011-03-01 – 2012-04-24 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01316913 · GlaxoSmithKline
2011-03 – 2012-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01202188 · Novartis Pharmaceuticals
2010-09 – 2012-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01294787 · Novartis Pharmaceuticals
2011-02 – 2011-11 · COPD
What this study did
NCT00929110 · Novartis
2009-06 – 2011-04 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01040689 · Boehringer Ingelheim
2010-01 – 2011-01 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00900731 · Novartis Pharmaceuticals
2009-06 – 2010-03 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00435760 · AstraZeneca
2007-02 – 2007-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
Phase 2/3 (1)
Chronic Obstructive Pulmonary Disease
NCT00463567 · Novartis
2007-04 – 2008-08 · Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
What this study did
Phase 2 (16)
Asthma
NCT02382510 · Theron Pharmaceuticals, Inc.
2015-04 – 2016-03 · Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT03084796 · Chiesi Farmaceutici S.p.A.
2017-07-28 – 2018-06-06 · COPD, Chronic Obstructive Pulmonary Disease
What this study did
NCT01708057 · AstraZeneca
2012-10 – 2012-12 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT01498081 · AstraZeneca
2012-03 – 2012-10 · COPD
What this study did
NCT01587079 · Pearl Therapeutics, Inc.
2012-04 – 2012-10 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01566773 · Pearl Therapeutics, Inc.
2012-03 – 2012-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01426009 · Sunovion Respiratory Development Inc.
2011-08 – 2011-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01068613 · Novartis Pharmaceuticals
2010-01 – 2010-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00950807 · GlaxoSmithKline
2009-09-01 – 2010-03-15 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00939211 · AstraZeneca
2009-06 – 2009-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00868231 · AstraZeneca
2009-03 – 2009-07 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00501852 · Novartis Pharmaceuticals
2007-07 – 2007-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02242279 · Boehringer Ingelheim
2004-06 – 2004-12 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 1/2 (2)
Chronic Obstructive Pulmonary Disease
NCT01176903 · Chiesi Farmaceutici S.p.A.
2010-08 – 2011-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00871182 · Pearl Therapeutics, Inc.
2009-03 – 2009-09 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 1 (3)
Chronic Obstructive Pulmonary Disease
NCT02059434 · AstraZeneca
2013-09-01 – 2014-10-06 · Chronic Obstructive Pulmonary Disease (COPD), Asthma
What this study did
NCT00532350 · Novartis
2007-07 – 2008-01 · Chronic Obstructive Pulmonary Disease
What this study did
Other / comorbidity
NCT03097380 · AstraZeneca
2017-04-26 – 2017-12-30 · Healthy Volunteers
What this study did
Phase 4 (15)
Chronic Obstructive Pulmonary Disease
NCT06282861 · Fundacio Privada Mon Clinic Barcelona
2024-02-29 – 2025-01-23 · Chronic Obstructive Pulmonary Disease
What this study did
NCT05165485 · Theravance Biopharma
2022-01-07 – 2023-11-20 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02603393 · Novartis Pharmaceuticals
2015-11-20 – 2017-07-18 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02275481 · Sumitomo Pharma America, Inc.
2014-11 – 2016-09-14 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT05506865 · National Institute of Respiratory Diseases, Mexico
2012-09 – 2016-07 · COPD
What this study did
NCT01727024 · Novartis Pharmaceuticals
2013-04 – 2015-11 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02473237 · National Institute of Respiratory Diseases, Mexico
2013-04 – 2015-08 · COPD
What this study did
NCT02039050 · University of Dundee
2014-02 – 2015-07 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01437748 · University of Milan
2011-08 – 2014-09 · Healthy, COPD
What this study did
NCT01715311 · Novartis Pharmaceuticals
2012-11 – 2013-09 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00424528 · Sumitomo Pharma America, Inc.
2006-12 – 2007-10 · Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Asthma
NCT02682862 · University of Dundee
2016-07-11 – 2019-05-22 · Asthma
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Chronic Obstructive Pulmonary Disease
NCT03976713 · Henan University of Traditional Chinese Medicine
2019-06 – 2020-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00846586 · Novartis Pharmaceuticals
2009-03 – 2010-03 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00877383 · Novartis Pharmaceuticals
2009-04 – 2010-02 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
Phase 4 (4)
Chronic Obstructive Pulmonary Disease
NCT02853123 · Boehringer Ingelheim
2016-09-22 – 2017-08-14 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00783250 · IRCCS Azienda Ospedaliero-Universitaria di Bologna
2008-09 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01465906 · Shanghai Zhongshan Hospital
2010-11 – 2011-11 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01124422 · GlaxoSmithKline
2010-07-19 – 2011-05-02 · Pulmonary Disease, Chronic Obstructive
What this study did
Early phase / not applicable (1)
Chronic Obstructive Pulmonary Disease
NCT03083067 · Peking University First Hospital
2017-03-20 – 2022-03-16 · COPD Exacerbation, Air Pollution
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tiotropium Bromide: this drugApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race
TozorakimabPhase 2Monoclonal antibodyIL-33Partial signal
NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed
Umeclidinium (Incruse Ellipta)Phase 2Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873)
NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05)
VerekitugPhase 2Monoclonal antibodyTSLP receptorReliable signal
NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02)
ItepekimabDiscontinuedMonoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication
NavafenterolDiscontinued—Muscarinic receptors and beta-2 adrenergic receptors, Muscarinic receptors (M1-M3) and beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 20 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tiotropium bromide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 4AsthmaNot yet recruiting
Est. primary completion 2027-01 · NCT06679465 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 4Bronchial Obstruction, Premature BirthNot yet recruiting
Est. primary completion 2029-05-01 · NCT07827859 · CT.gov ↗
What to watch

See the full readout calendar ↗